NADAC acquisition cost data for ORENCIA 125 MG/ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
| 00003218811 | $1,231.29 | 2022-01-01 | Rx |
Generic: Abatacept | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $171.0M | 33,983 | 4,897 | $1,109.77 |
| 2020 | $172.2M | 31,561 | 4,438 | $1,173.27 |
| 2021 | $168.5M | 29,820 | 4,269 | $1,238.82 |
| 2022 | $170.8M | 29,460 | 4,109 | $1,300.71 |
| 2023 | $178.4M | 29,171 | 4,032 | $1,386.44 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $22.2M | 3,844 | 559 |
| Texas | $14.3M | 2,288 | 314 |
| New York | $14.1M | 2,130 | 312 |
| Florida | $9.7M | 2,095 | 372 |
| California | $9.6M | 2,205 | 312 |
| Michigan | $9.0M | 1,487 | 202 |
| Florida | $8.9M | 1,415 | 215 |
| Pennsylvania | $8.0M | 1,311 | 182 |
| Texas | $7.4M | 1,634 | 237 |
| Ohio | $6.4M | 1,038 | 162 |
| Massachusetts | $6.2M | 967 | 141 |
| Puerto Rico | $5.9M | 1,093 | 138 |
| North Carolina | $5.5M | 895 | 125 |
| Illinois | $5.2M | 821 | 115 |
| Wisconsin | $4.5M | 779 | 98 |
| Washington | $4.3M | 724 | 108 |
| Georgia | $4.3M | 729 | 100 |
| New York | $4.3M | 874 | 130 |
| New Jersey | $4.2M | 678 | 97 |
| Tennessee | $3.7M | 604 | 84 |
| Colorado | $3.7M | 665 | 85 |
| Indiana | $3.4M | 562 | 72 |
| Missouri | $3.2M | 481 | 78 |
| New Jersey | $3.2M | 658 | 96 |
| South Carolina | $3.2M | 494 | 72 |
| Connecticut | $2.7M | 395 | 67 |
| Pennsylvania | $2.6M | 583 | 87 |
| Oregon | $2.5M | 434 | 66 |
| Virginia | $2.5M | 417 | 59 |
| Alabama | $2.5M | 406 | 53 |
| Arizona | $2.4M | 397 | 65 |
| Kentucky | $2.3M | 389 | 63 |
| Minnesota | $2.1M | 321 | 48 |
| Maryland | $2.0M | 295 | 61 |
| Oklahoma | $1.9M | 316 | 46 |
| New Mexico | $1.8M | 311 | 42 |
| Alabama | $1.7M | 361 | 53 |
| Louisiana | $1.6M | 340 | 44 |
| North Carolina | $1.5M | 303 | 46 |
| Mississippi | $1.5M | 239 | 34 |
| Idaho | $1.3M | 229 | 29 |
| Arkansas | $1.3M | 227 | 31 |
| Louisiana | $1.3M | 228 | 28 |
| Georgia | $1.2M | 249 | 39 |
| Iowa | $1.1M | 196 | 31 |
| New Hampshire | $910.1K | 130 | 19 |
| Ohio | $903.2K | 218 | 28 |
| Michigan | $883.1K | 209 | 23 |
| Maryland | $856.7K | 172 | 27 |
| Massachusetts | $828.9K | 184 | 25 |
| Utah | $827.6K | 133 | 18 |
| Kansas | $800.0K | 136 | 21 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.